These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 21569815)

  • 1. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.
    Agallou M; Margaroni M; Karagouni E
    Vaccine; 2011 Jul; 29(31):5053-64. PubMed ID: 21569815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis.
    Agallou M; Smirlis D; Soteriadou KP; Karagouni E
    Vaccine; 2012 Jul; 30(34):5086-93. PubMed ID: 22704924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection.
    Parody N; Soto M; Requena JM; Alonso C
    Parasite Immunol; 2004; 26(6-7):283-93. PubMed ID: 15541032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells.
    Carrión J; Folgueira C; Alonso C
    Vaccine; 2008 May; 26(20):2537-44. PubMed ID: 18400342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.
    Bhaumik S; Basu R; Sen S; Naskar K; Roy S
    Vaccine; 2009 Feb; 27(9):1306-16. PubMed ID: 19162111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection.
    Ahuja SS; Reddick RL; Sato N; Montalbo E; Kostecki V; Zhao W; Dolan MJ; Melby PC; Ahuja SK
    J Immunol; 1999 Oct; 163(7):3890-7. PubMed ID: 10490989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
    Rafati S; Zahedifard F; Azari MK; Taslimi Y; Taheri T
    Exp Parasitol; 2008 Mar; 118(3):393-401. PubMed ID: 18093586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis.
    Carrillo E; Crusat M; Nieto J; Chicharro C; Thomas Mdel C; Martínez E; Valladares B; Cañavate C; Requena JM; López MC; Alvar J; Moreno J
    Vaccine; 2008 Mar; 26(15):1902-11. PubMed ID: 18321614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania infantum FML pulsed-dendritic cells induce a protective immune response in murine visceral leishmaniasis.
    Foroughi-Parvar F; Hatam GR; Sarkari B; Kamali-Sarvestani E
    Immunotherapy; 2015; 7(1):3-12. PubMed ID: 25572475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imprinting of BALB/c mice with low Leishmania infantum parasite dose markedly protects spleen against high-dose challenge.
    Ferrua B; Luci C; Le Fichoux Y; Paul A; Marty P
    Vaccine; 2006 Jan; 24(5):589-96. PubMed ID: 16157427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
    Rafati S; Zahedifard F; Nazgouee F
    Vaccine; 2006 Mar; 24(12):2169-75. PubMed ID: 16325969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS; Bayih AG; Gedamu L
    Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.